Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved

The China Food and Drug Administration (CFDA) has approved two combinations of Bristol-Myers Squibb’s (BMS) hepatitis C medicines. A combination of Daklinza (daclatasvir) with Sunvepra (asunaprevir) has been approved for patients with genotype 1b of the disease, while Daklinza in combination with Gilead’s Sovaldi (sofosbuvir) has been approved across genotypes 1–6.

Sovaldi alone, which has brought Gilead billions of dollars in sales elsewhere around the world, is not approved in China (it is currently under review by the CFDA). These combinations represent China’s first approval of drugs for hepatitis C that do not also require interferon or ribavirin treatment, which are associated with serious side effects.

As Business editor, Phillip's aim is to highlight to readers the exciting and innovative chemistry going on in the commercial sector, as well as keeping them abreast of trends and developments in the world of chemistry businesses.View full profile

More Phillip Broadwith

Topics